EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Clinical characteristics and treatment outcomes in patients with double‐seronegative myasthenia gravis

Rodrigo Martinez-Harms iD, Carolina Barnett, Monica Alcantara, Vera Bril iD

European Journal of Neurology · 2024-01 · 31 (1)

DOI: 10.1111/ene.16022 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Neurology, online erschienen am 16.08.2023. Verfasst von Rodrigo Martinez-Harms und 3 weiteren Autor:innen. Beteiligte Einrichtung: Ellen and Martin Prosserman Centre for Neuromuscular Diseases, Toronto General Hospital, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Receptor Protein-Tyrosine Kinases, Myasthenia Gravis. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and purpose Double‐seronegative myasthenia gravis (dSNMG) is defined as myasthenia gravis (MG) without detectable or low affinity antibodies to acetylcholine receptor (AChR) and muscle‐specific kinase (MuSK). There are limited data on detailed clinical features and outcomes after treatment in dSNMG patients. The aim was to describe the clinical characteristics and outcomes in dSNMG patients based on MG scales.

Methods

A retrospective study was performed of patients diagnosed with MG who had negative AChR or MuSK antibodies and they were compared with an AChR‐positive MG cohort. Correlations were made with data from the first and last clinic visits, between demographics, clinical characteristics, treatment and disease severity, based on the Myasthenia Gravis Foundation of America category, Myasthenia Gravis Impairment Index (MGII), Patient Acceptable Symptom State and simple single question (SSQ).

Results

Eighty patients met the inclusion criteria for dSNMG. The baseline MGII and SSQ scores in the dSNMG cohort showed no significant differences from the AChR group ( p = 0.94 and p = 0.46). The dSNMG cohort MGII and SSQ scores improved significantly at the last clinical evaluation ( p = 0.001 and p = 0.047). The MGII improvement in the AChR cohort was significantly better ( p = 0.003).

Conclusions

The initial severity of dSNMG based on clinical scores is similar to antibody‐positive MG patients. There is significant clinical improvement in dSNMG patients after therapy, measured in the last clinical evaluation. This supports an immune pathophysiology of many dSNMG patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptor Protein-Tyrosine KinasesMyasthenia GravisHumansRetrospective StudiesAutoantibodiesReceptors, CholinergicTreatment Outcome

Stichwörter der Autor:innen

double-seronegative myasthenia gravismyasthenia gravisoutcometreatment

Substanzen

Receptor Protein-Tyrosine KinasesAutoantibodiesReceptors, Cholinergic

Autor:innen und Institutionen

  • Ellen and Martin Prosserman Centre for Neuromuscular Diseases, Toronto General Hospital, Toronto, Ontario, Canada.
  • University Health Network, University of Toronto, Toronto, Ontario, Canada.

ORCID-Profile: Rodrigo Martinez-Harms, Vera Bril

Zitieren

APA

Martinez-Harms, R., Barnett, C., Alcantara, M., & Bril, V. (2024). Clinical characteristics and treatment outcomes in patients with double‐seronegative myasthenia gravis. European Journal of Neurology, 31(1). https://doi.org/10.1111/ene.16022

Vancouver

Martinez-Harms R, Barnett C, Alcantara M, Bril V. Clinical characteristics and treatment outcomes in patients with double‐seronegative myasthenia gravis. European Journal of Neurology. 2024;31(1). doi:10.1111/ene.16022

BibTeX
@article{MartinezHarms2024,
  author = {Martinez-Harms, Rodrigo and Barnett, Carolina and Alcantara, Monica and Bril, Vera},
  title = {Clinical characteristics and treatment outcomes in patients with double‐seronegative myasthenia gravis},
  journal = {European Journal of Neurology},
  year = {2024},
  volume = {31},
  number = {1},
  doi = {10.1111/ene.16022}
}
Kostenlos starten →